Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
FDA Approves Pavblu (aflibercept-ayyh), a Biosimilar to Eylea
FDA approves Pavblu (aflibercept-ayyh), a biosimilar to Eylea, for treating neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).
© Copyright 2024. All Rights Reserved by MedPath